Clinical Features, Treatment Strategies, and Outcomes of Hypophysitis Induced by Ipilimumab
Overview
This study reviews 76 cases of ipilimumab-induced hypophysitis, highlighting its clinical features, treatment strategies, and outcomes.
Background
Ipilimumab is an immune checkpoint inhibitor that can lead to immune-related endocrine adverse events, particularly hypophysitis. Understanding the clinical characteristics and management of this condition is crucial for timely diagnosis and treatment.
Data Highlights
Characteristic
Value
Median Age
58 years (range 26–82)
Male Percentage
61.8%
Median Time to Onset
9 weeks (range 1.6–37)
Headache Incidence
68.0%
Fatigue Incidence
64.0%
Secondary Adrenal Insufficiency
93.4%
Complete Hormonal Recovery
7.9%
Key Findings
Ipilimumab-induced hypophysitis typically occurs within the first 10 weeks of treatment.
Common symptoms include headache (68.0%) and fatigue (64.0%).
Secondary adrenal insufficiency is prevalent, with low cortisol and ACTH levels in 93.4% and 89.8% of patients, respectively.
Pituitary enlargement is observed in 71.0% of patients undergoing MRI.
Glucocorticoid replacement is the primary treatment, with clinical improvement seen in 82.9% of patients.
Long-term endocrine dysfunction is common, with only 7.9% achieving complete hormonal recovery.
Clinical Implications
Clinicians should be vigilant for signs of hypophysitis in patients receiving ipilimumab, particularly within the first 10 weeks of therapy.
Conclusion
Ipilimumab-induced hypophysitis is a significant adverse effect characterized by early onset and frequent secondary adrenal insufficiency.
